“客药第一股”董事长因何领罚单？

Core Viewpoint - Jia Ying Pharmaceutical (002198.SZ) and its responsible persons received a warning and fines from the Guangdong Securities Regulatory Bureau due to failure to timely disclose related party transactions involving approximately 220 million yuan [2][4][6] Group 1: Regulatory Actions - The company and its executives, including Chairman Li Neng, were issued a warning and fines due to the undisclosed borrowing of 220 million yuan from a related party, Hunan Yao Juneng Pharmaceutical Co., Ltd. [2][4][6] - The borrowing occurred between October 2024 and January 2025, with amounts ranging from 40,000 to 59.99 million yuan, totaling approximately 170 million yuan in 2024 and 50 million yuan in January 2025 [4][6] - The total amount borrowed represented 28.83% of Jia Ying Pharmaceutical's latest audited net assets [4] Group 2: Internal Changes and Financial Performance - The company has experienced significant internal changes, including the transfer of 7% of shares from shareholder Chen Shaobin to Yang Tianhe, making Yang Tianhe the second-largest shareholder [7] - Li Neng was elected as chairman on August 23, 2024, with a three-year term, amidst a series of resignations from key positions, including the financial director [7][8] - Jia Ying Pharmaceutical's revenue has declined for two consecutive years, with a 19.11% drop in 2023 and a further 29.46% decline in 2024, resulting in revenues of 533 million yuan and 376 million yuan, respectively [8] - The company's net profit also decreased significantly, with a 21.88% drop in 2023 and a 39.94% drop in 2024, leading to net profits of 34 million yuan and 21 million yuan, respectively [8] - In the first quarter of 2024, the company reported a revenue of 122 million yuan, a year-on-year increase of 28.83%, and a net profit of 15 million yuan, reflecting a significant growth of 197.23% [8]